Compare Mongodb Inc (MDB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Sana Biotechnology Inc — how do they compare? Mongodb Inc trades at $384.69 (market cap $29.24B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Mongodb Inc is far larger — about 34.9× Sana Biotechnology Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Sana Biotechnology Inc for 23 Days on average.
| MDB | SANA | |
|---|---|---|
Market Cap | $29.24B | $836.71M |
Volume | 1,304,995 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $472.29 | $5.92 |
52-Week Low | $225.95 | $2.68 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | $26.86B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $383.26, up 5.57% today, with a bullish technical signal and strong analyst support. The stock is near resistance at $384 after recent volatility from a CEO transition. Fundamentally, revenue growth is robust, reaching $2.01B in 2025, but profitability remains negative with a net loss of $129M. Recent Investor Day highlighted AI product launches and raised long-term targets, fueling optimism.
Outlook is positive with 80% analyst buy ratings and a $456.76 consensus target, but risks include persistent losses, high valuation multiples, and execution challenges amid leadership changes. The stock offers growth exposure to AI-driven database demand, yet investors must weigh profitability concerns against expansion potential.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
